View from City Road: Depression among the drug stocks
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Just when investors in drug stocks must have felt they were out of the woods, the doomsters seem to have re- gained the upper hand. Latest to join in is Salomon Brothers, which confessed to over-optimism about its earnings expectations for all four big UK drug stocks - SmithKline Beecham, Wellcome, Glaxo and Zeneca - and promptly downgraded the lot.
Given that stockbrokers are pre- disposed to be over-optimistic about the companies they follow - success is better for business, and more fun - this burst of pessimism warrants attention. It has been provoked by renewed worries about pressure on drug prices, slowing sales growth and the limited response of the industry so far on costs.
They are the same fears that were voiced a year or more ago. But since then we have had a false dawn, created by a flurry of corporate activity in the US and the busy cheque books of the likes of Merck, SmithKline Beecham, Roche and Elf Sanofi, among others.
The sector, which was once more than 10 per cent cheaper than the market, is now almost as expensive. But its earnings growth, at around 12 per cent this year, is likely to be significantly below the market's.
All four big UK stocks have their corporate worries too. Wellcome has seen a series of key and unexplained management changes, and faces impending competition for Zovirax, the anti-viral drug that contributes some 60 per cent of its profits. Glaxo - with or without a big US acquisition - is undergoing a deeply upsetting revolution in its corporate culture.
SmithKline Beecham faces a tough task integrating its purchase of a US pharmaceutical benefit manager. And Zeneca still has to face up to the fact that it is too small to be a pure drug company, but too incoherent as a drug to agrochemcials combine. Sometimes it seems as if the woods stretch to the horizon.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments